Literature DB >> 35463041

A review on cullin neddylation and strategies to identify its inhibitors for cancer therapy.

Iqra Bano1, Moolchand Malhi2, Min Zhao3, Liviu Giurgiulescu4, Hira Sajjad2, Marek Kieliszek5.   

Abstract

The cullin-RING E3 ligases (CRLs) are the biggest components of the E3 ubiquitin ligase protein family, and they represent an essential role in various diseases that occur because of abnormal activation, particularly in tumors development. Regulation of CRLs needs neddylation, a post-translational modification involving an enzymatic cascade that transfers small, ubiquitin-like NEDD8 protein to CRLs. Many previous studies have confirmed neddylation as an enticing target for anticancer drug discoveries, and few recent studies have also found a significant increase in advancement in protein neddylation, including preclinical and clinical target validation to discover the neddylation inhibitor compound. In the present review, we first presented briefly the essence of CRLs' neddylation and its control, systematic analysis of CRLs, followed by the description of a few recorded chemical inhibitors of CRLs neddylation enzymes with recent examples of preclinical and clinical targets. We have also listed various structure-based pointing of protein-protein dealings in the CRLs' neddylation reaction, and last, the methods available to discover new inhibitors of neddylation are elaborated. This review will offer a concentrated, up-to-date, and detailed description of the discovery of neddylation inhibitors. © King Abdulaziz City for Science and Technology 2022.

Entities:  

Keywords:  Cancer; Cullin-RING E3 ligase; Inhibitor; NEDD8; Neddylation

Year:  2022        PMID: 35463041      PMCID: PMC8964847          DOI: 10.1007/s13205-022-03162-x

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.406


  108 in total

1.  Perspectives on the development of first-in-class protein degraders.

Authors:  Kalyn M Rambacher; Matthew F Calabrese; Masaya Yamaguchi
Journal:  Future Med Chem       Date:  2021-05-21       Impact factor: 3.808

2.  Discovery of a natural product inhibitor targeting protein neddylation by structure-based virtual screening.

Authors:  Hai-Jing Zhong; Victor Pui-Yan Ma; Zhen Cheng; Daniel Shiu-Hin Chan; Hong-Zhang He; Ka-Ho Leung; Dik-Lung Ma; Chung-Hang Leung
Journal:  Biochimie       Date:  2012-06-16       Impact factor: 4.079

Review 3.  Stem-loop binding protein and metal carcinogenesis.

Authors:  Beatrix R Bradford; Chunyuan Jin
Journal:  Semin Cancer Biol       Date:  2021-08-18       Impact factor: 15.707

4.  Piperidinyl Ureas Chemically Control Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation.

Authors:  Jared T Hammill; Daniel C Scott; Jaeki Min; Michele C Connelly; Gloria Holbrook; Fangyi Zhu; Amy Matheny; Lei Yang; Bhuvanesh Singh; Brenda A Schulman; R Kiplin Guy
Journal:  J Med Chem       Date:  2018-03-26       Impact factor: 7.446

5.  E1 Enzymes as Therapeutic Targets in Cancer.

Authors:  Samir H Barghout; Aaron D Schimmer
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 6.  Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management.

Authors:  Perry Wu; Ohad Oren; Morie A Gertz; Eric H Yang
Journal:  Curr Oncol Rep       Date:  2020-06-08       Impact factor: 5.075

7.  Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-κB-CCL2 signaling in lung cancer.

Authors:  Lisha Zhou; Yanyu Jiang; Xiaojun Liu; Lihui Li; Xuguang Yang; Changsheng Dong; Xiaoli Liu; Yuli Lin; Yan Li; Jinha Yu; Rui He; Shenglin Huang; Guangwei Liu; Yanmei Zhang; Lak Shin Jeong; Robert M Hoffman; Lijun Jia
Journal:  Oncogene       Date:  2019-06-26       Impact factor: 9.867

Review 8.  Advances in Cancer Treatment by Targeting the Neddylation Pathway.

Authors:  Wenbin Gai; Zhiqiang Peng; Cui Hua Liu; Lingqiang Zhang; Hong Jiang
Journal:  Front Cell Dev Biol       Date:  2021-04-08

Review 9.  Regulation of cell cycle drivers by Cullin-RING ubiquitin ligases.

Authors:  Sang-Min Jang; Christophe E Redon; Bhushan L Thakur; Meriam K Bahta; Mirit I Aladjem
Journal:  Exp Mol Med       Date:  2020-10-02       Impact factor: 8.718

10.  Targeting RNA-binding proteins in acute and chronic leukemia.

Authors:  Irina A Elcheva; Vladimir S Spiegelman
Journal:  Leukemia       Date:  2020-11-04       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.